Table 1.

Observational studies: switching from originator infliximab to CT-P13 biosimilar.

Study	Country, year	CD	UC	Switch CD/UC	Follow-up week	Stop, %	AEs, %	ADA, %
Jung et al.35	Korea, 2015	59	51	27/9	54	7.4/33.3	2.7	n.a.
Sieczkowska et al.25	Poland, 2016	32	7	32/7	32	6.25/ 43	2.5	n.a.
Smits et al.26	The Netherlands, 2017	57	24	57/24	52	7	6	8
Guerrero Puente et al.28	Spain, 2017	23	13	23/13	33.6	2.7	8.3	n.a.
Eberl et al.27	Finland, 2017	32	30	32/30	16	0	4.8	3.2
Fiorino et al.29	Italy, 2017	313	234	97	24	5.2	12.1	n.a.
Argüelles-Arias et al.23	Spain, 2017	67	31	67/31	52	12.2	11.2	n.a.
Buer et al.30	Norway, 2017	99	44	99/44	26	0.7	14.1/2.2	3.5
Razanskaite et al.38	United Kingdom, 2017	118	23	118/23	n.a.	28.7	n.a.	40
Schmitz et al.22	The Netherlands, 2017	86	47	86/47	52	26	9.8	6
Jahnsen and Kaasen Jørgensen32	Norway, 2017	37	19	37/19	26	0	0	n.a.
Kolar et al.34	Czech Republic, 2017	56	18	56/18	56	3.6/11.1	n.a.	6
Tursi et al.39	Italy, 2017	0	29	0/11	52	n.a.	0	n.a.
Avouac et al.40	France, 2018	41	23	41/23	34	4.7	4.7	n.a.
Binkhorst et al.44	The Netherlands, 2018	135	62	135/62	16	10	6.1	3
Kang et al.41	Korea, 2018	32	6	32/6	52	7.8	60.5	2.6
Strik et al.42	The Netherlands, 2018	61	59	60/58	16	0	80	4
Ratnakumaran et al.43	United Kingdom, 2018	173	14	173/14	52	2.1	4.7	n.a.
Bergqvist et al.45	Sweden, 2018	195	118	195/118	52	n.a.	2.2	2.7
Armuzzi et al.46	Italy, 2018	87	68	87/68	52	3.9	11.6	n.a.
Smits et al.48	The Netherlands, 2018	57	24	57/24	104	12.1	9.6	8.4
Høivik et al.49	Norway, 2018	99	44	99/43	72	8.4	2.8	1.4

ADA, antidrug antibody; AEs, adverse events; CD, Crohn’s disease; n.a., not applicable; UC, ulcerative colitis.